Literature DB >> 20346647

Discovering moderate-risk breast cancer susceptibility genes.

Antoinette Hollestelle1, Marijke Wasielewski, John W M Martens, Mieke Schutte.   

Abstract

To date, five moderate-risk breast cancer susceptibility genes have been convincingly identified: CHEK2, ATM, BRIP1, PALB2, and NBS1. Moderate-risk breast cancer alleles confer increased breast cancer risks of two to fourfold compared to the 10% risk in the general population. In contrast to the high-risk BRCA1 and BRCA2 genes, moderate-risk genes typically have a limited number of variants that confer breast cancer risks. The prevalence of the variants usually varies widely among different geographical or ethnic populations, ranging from essentially absent up to 1.5% (i.e. 'rare' variants). Since moderate-risk breast cancer alleles are clinically not recognizable when inherited as single mutant, one usually encounters them in a polygenic setting and consequently in incomplete cosegregation with the breast cancer phenotype. As a result, discovery of moderate-risk breast cancer genes requires conclusive statistical evidence from association studies of hundreds of breast cancer cases and population-matched controls.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20346647     DOI: 10.1016/j.gde.2010.02.009

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  45 in total

1.  Fine mapping of 14q24.1 breast cancer susceptibility locus.

Authors:  Phoebe Lee; Yi-Ping Fu; Jonine D Figueroa; Ludmila Prokunina-Olsson; Jesus Gonzalez-Bosquet; Peter Kraft; Zhaoming Wang; Kevin B Jacobs; Meredith Yeager; Marie-Josèphe Horner; Susan E Hankinson; Amy Hutchinson; Nilanjan Chatterjee; Montserrat Garcia-Closas; Regina G Ziegler; Christine D Berg; Saundra S Buys; Catherine A McCarty; Heather Spencer Feigelson; Michael J Thun; Ryan Diver; Ross Prentice; Rebecca Jackson; Charles Kooperberg; Rowan Chlebowski; Jolanta Lissowska; Beata Peplonska; Louise A Brinton; Margaret Tucker; Joseph F Fraumeni; Robert N Hoover; Gilles Thomas; David J Hunter; Stephen J Chanock
Journal:  Hum Genet       Date:  2011-09-30       Impact factor: 4.132

2.  Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer.

Authors:  Silvia Casadei; Barbara M Norquist; Tom Walsh; Sunday Stray; Jessica B Mandell; Ming K Lee; John A Stamatoyannopoulos; Mary-Claire King
Journal:  Cancer Res       Date:  2011-02-01       Impact factor: 12.701

3.  CHEK2*1100delC homozygosity in the Netherlands--prevalence and risk of breast and lung cancer.

Authors:  Petra E A Huijts; Antoinette Hollestelle; Brunilda Balliu; Jeanine J Houwing-Duistermaat; Caro M Meijers; Jannet C Blom; Bahar Ozturk; Elly M M Krol-Warmerdam; Juul Wijnen; Els M J J Berns; John W M Martens; Caroline Seynaeve; Lambertus A Kiemeney; Henricus F van der Heijden; Rob A E M Tollenaar; Peter Devilee; Christi J van Asperen
Journal:  Eur J Hum Genet       Date:  2013-05-08       Impact factor: 4.246

4.  Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.

Authors:  Antoinette Hollestelle; Cory Pelletier; Maartje Hooning; Ellen Crepin; Mieke Schutte; Maxime Look; J Margriet Collee; Anja Nieuwlaat; Lambert C J Dorssers; Caroline Seynaeve; Yurii S Aulchenko; John W M Martens; Ans M W van den Ouweland; Joanne B Weidhaas
Journal:  Breast Cancer Res Treat       Date:  2010-07-30       Impact factor: 4.872

Review 5.  Growing recognition of the role for rare missense substitutions in breast cancer susceptibility.

Authors:  Sean V Tavtigian; Georgia Chenevix-Trench
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

Review 6.  Genotype/Phenotype correlations in patients with hereditary breast cancer.

Authors:  Maike Wittersheim; Reinhard Büttner; Birgid Markiefka
Journal:  Breast Care (Basel)       Date:  2015-02       Impact factor: 2.860

7.  RAP80 is critical in maintaining genomic stability and suppressing tumor development.

Authors:  Zhengyu Yin; Daniel Menendez; Michael A Resnick; John E French; Kyathanahalli S Janardhan; Anton M Jetten
Journal:  Cancer Res       Date:  2012-08-15       Impact factor: 12.701

8.  Response to DNA damage of CHEK2 missense mutations in familial breast cancer.

Authors:  Wendy Roeb; Jake Higgins; Mary-Claire King
Journal:  Hum Mol Genet       Date:  2012-03-13       Impact factor: 6.150

9.  CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations.

Authors:  Robert R McWilliams; Eric D Wieben; Kari G Chaffee; Samuel O Antwi; Leon Raskin; Olufunmilayo I Olopade; Donghui Li; W Edward Highsmith; Gerardo Colon-Otero; Lauren G Khanna; Jennifer B Permuth; Janet E Olson; Harold Frucht; Jeanine Genkinger; Wei Zheng; William J Blot; Lang Wu; Luciana L Almada; Martin E Fernandez-Zapico; Hugues Sicotte; Katrina S Pedersen; Gloria M Petersen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-07-23       Impact factor: 4.254

10.  Development of a novel PTT assay for mutation detection in PALB2 large exons and PALB2 screening in medullary breast cancer.

Authors:  Nikoleta Poumpouridou; Nikolaos Goutas; Christina Tsionou; Kleanthi Dimas; Evi Lianidou; Christos Kroupis
Journal:  Fam Cancer       Date:  2016-04       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.